Artificial intelligence (AI) is transforming industries, including the life sciences industry, from drug discovery and diagnostics to medical devices and manufacturing. With that transformation comes a critical challenge: crafting strategies to protect AI-related innovations. Strategies for protecting AI innovations are unique. Approaching IP protections for AI innovations in the same way as approaching IP protections
Latest from Healthcare Law Insights
Dealmaking in the Age of AI: IP, Licensing, and Spin-Out Strategies for AI-Enhanced Drug Discovery
This is the third in a series of blog posts focused on AI and clinical trials/research space, highlighting topics to be discussed at the upcoming BIO International convention on June 22-25, 2026.
AI is transforming drug discovery faster than deal structures can adapt. Traditional licensing frameworks were built for linear innovation: researcher invents, institution owns,
Protocol Design and Recruitment Risks: AI’s Hidden Compliance Traps in Clinical Trials
This is the second in a series of blog posts focused on AI and clinical trials/research space, highlighting topics to be discussed at the upcoming BIO International convention on June 22-25, 2026.
Introduction
Your latest trial sponsor is using AI to accelerate protocol development and patient recruitment,[1] cutting timelines that once took months
AI in the Fine Print: Why Your Contracts May Not Be Ready
Register for our webinar, AI in Your Organization: Are Your Contracts Keeping Up?, on May 19 at noon CT, presented by Kris Kappel and Maggie Mannebach.
Artificial intelligence is no longer an emerging technology—it is embedded in the mainstream enterprise software, platforms, and vendor services that organizations rely on every day. In many cases,
Before AI Meets Your Biobank: Five Must-Do Steps for Research Institutions
This is the first in a series of blog posts focused on AI and clinical trials/research space, highlighting topics to be discussed at the upcoming BIO International convention on June 22-25, 2026.
A major research institution combines 15 years of patient genomic data with metabolomic profiles and clinical outcomes, feeding it into an AI model
Tennessee Draws a Line: New Law Bars AI from Posing as Mental Health Professionals
On April 1, 2026, Governor Bill Lee signed Senate Bill 1580 into law, making Tennessee among the first states to specifically regulate how AI can be marketed and used in the mental health space. The new law takes effect July 1, 2026.
AI, Privilege, and Confidential Business Information: The Heppner Case and What It Means for Life Sciences Teams
Earlier this month, Judge Rakoff of the Southern District of New York issued a first-of-its-kind ruling in United States v. Heppner. The case involved a criminal defendant, Heppner, who used a public generative AI platform (Claude) to “prepare reports that outlined his defense strategy (what he might argue with respect to the facts and the
3 Things Every Business Must Know About AI — Before It Is Too Late
Everyone is talking about AI, but not everyone understands what AI is. AI, or artificial intelligence, refers to technology that enables machines to perform tasks that traditionally required human thinking—things like reading, writing, analyzing information, and making decisions.
A particularly powerful form of AI today is the large language model (or LLM), which is a
Data and Research Rights: Structuring Around Institutional Control
This is the third in a series of articles designed to provide SXSW and LSI USA ’26 attendees and other MedTech professionals with practical considerations for efficiently executing mission-critical life science deals. On March 15, during SXSW, Husch Blackwell’s healthcare team will host two panels, bringing together founders and investors from healthcare, technology, and early-stage
New DOJ Regulations on Bulk Sensitive Personal Data Transfers
Department of Justice Bulk Sensitive Personal Data Transfer Rule (28 CFR Part 202)
This post is part of our The Top 2025 Privacy and Security Issues Still Shaping Healthcare series, in which our team of attorneys provides essential strategies and insights for healthcare privacy and security.
Overview
On February 28, 2024, President Biden signed Executive Order 14117,